Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;99(2):339-45.
doi: 10.3324/haematol.2012.081885. Epub 2013 Sep 13.

Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands

Affiliations

Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands

Saskia A M van de Schans et al. Haematologica. 2014 Feb.

Abstract

Survival rates determined at diagnosis are often too negative for cancer survivors. Conditional relative survival reflects actual prognosis during follow-up better. Data from all 54,015 patients newly diagnosed in the Netherlands with B-cell non-Hodgkin lymphoma during 1989-2008, aged 15-89 years (Netherlands Cancer Registry), were used. Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diagnosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for survivors of indolent B-cell non-Hodgkin lymphoma improved slightly with each additional year survived up to 91%. For patients with aggressive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and gradually thereafter to 93% after 16 years. There were differences between morphological entities. Initial differences in conditional relative survival at diagnosis between groups with different disease stages became smaller with increasing number of years survived. Age remained a prognostic indicator, also after prolonged follow-up. These results help caregivers to plan optimal surveillance and inform patients about their actual prognosis during follow-up. Long-lasting excess mortality among patients with B-cell non-Hodgkin lymphoma indicates the need for additional care long after their diagnosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with B-cell non-Hodgkin lymphoma, according to entity.
Figure 2.
Figure 2.
(A) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with chronic lymphocytic leukemia, according to age group. (B) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with marginal zone lymphoma, according to age group. (C) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with follicular lymphoma, according to age group. (D) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with diffuse large B-cell lymphoma, according to age group.
Figure 3.
Figure 3.
(A) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with follicular lymphoma, according to Ann Arbor stage. (B) Conditional 5-year relative survival for every additional year survived after initial diagnosis of patients with diffuse large B-cell lymphoma (including central nervous system, cutaneous, mediastinal), according to Ann Arbor stage.
Figure 4.
Figure 4.
Conditional 3-year relative survival for every additional year survived after initial diagnosis of patients with NHL according to grade and period of diagnosis.

References

    1. Curado MP, Edwards B, Shin HR, Storm H. Cancer Incidence in Five Continents. Vol. IX No. 160 ed. Lyon: International Agency of Research on Cancer (IARC) Scientific Publications; 2007
    1. van de Schans SA, Issa DE, Visser O, Nooijen P, Huijgens PC, Karim-Kos HE, et al. Diverging trends in incidence and mortality and improved survival of non-Hodgkin's lymphoma in the Netherlands 1989–2007. Ann Oncol. 2012;23(1):171–82 - PubMed
    1. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer. 2008;123(8): 1917–23 - PubMed
    1. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002;94(7):2015–23 - PubMed
    1. van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol. 2009;20(10):1697–702 - PubMed

Publication types

LinkOut - more resources